Acumen Pharmaceuticals (ABOS) Competitors

Inozyme Pharma (NASDAQ:INZY) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

Which has more volatility and risk, INZY or ABOS?

Inozyme Pharma has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500.

Do analysts prefer INZY or ABOS?

Inozyme Pharma currently has a consensus price target of $11.75, indicating a potential upside of 197.47%. Acumen Pharmaceuticals has a consensus price target of $7.33, indicating a potential upside of 591.82%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Inozyme Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inozyme Pharma	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44
Acumen Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media refer more to INZY or ABOS?

In the previous week, Inozyme Pharma had 26 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 35 mentions for Inozyme Pharma and 9 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.29 beat Inozyme Pharma's score of -0.04 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inozyme Pharma	4 Very Positive mention(s)	5 Positive mention(s)	14 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings & valuation, INZY or ABOS?

Inozyme Pharma is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inozyme Pharma	N/A	N/A	-$71.17M	-$1.69	-2.34
Acumen Pharmaceuticals	N/A	N/A	-$52.37M	-$1.94	-0.55

Do institutionals and insiders believe in INZY or ABOS?

88.3% of Inozyme Pharma shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 12.2% of Inozyme Pharma shares are held by insiders. Comparatively, 9.3% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is INZY or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -32.99% beat Inozyme Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inozyme Pharma	N/A	-88.42%	-57.02%
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%

Does the MarketBeat Community favor INZY or ABOS?

Inozyme Pharma received 36 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 82.89% of users gave Inozyme Pharma an outperform vote while only 72.97% of users gave Acumen Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Inozyme Pharma	Outperform Votes 63 82.89%	Underperform Votes 13 17.11%
Acumen Pharmaceuticals	Outperform Votes 27 72.97%	Underperform Votes 10 27.03%

Summary

Inozyme Pharma and Acumen Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.